STERIS (NYSE: STE - Get Free Report) and QHSLab (OTCMKTS:USAQ - Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, dividends, analyst recommendations, profitability and earnings. Valuation and Earnings This table compares STERIS and QHSLab"s gross
Explore Steris' (STE) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
STERIS (NYSE: STE) executives highlighted broad-based third-quarter fiscal 2026 growth, improved earnings, and ongoing tariff headwinds during the company's earnings call, while maintaining full-year guidance and pointing to a more challenging comparison in the fourth quarter. Third-quarter results: revenue up 9%, EPS up 9% Chief Financial Officer Karen Burton said third-quarter revenue from continuing operations rose
STERIS offers a resilient, high-quality business model with some premium valuation, benefiting from hard-to-replicate sterilization networks and stable healthcare procedure volumes. Recent quarterly results included on-target 8% organic revenue growth but margin pressure from tariffs, with management raising tariff impact guidance by $10 million. STE stands to gain from stricter ethylene oxide (EtO) regulations, as compliance costs favor large, established players and will drive more outsourcing to its facilities.
Total Revenue Growth: 9% increase as reported.Constant Currency Organic Revenue Growth: 8% increase.Gross Margin: Declined 70 basis points to 43.9%.EBIT Margin
STERIS plc (STE) Q3 2026 Earnings Call Transcript
STERIS shares slide after hours as Q3 earnings meet estimates and revenues beat, with investors focused on gross margin contraction despite solid growth.
The headline numbers for Steris (STE) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Steris (STE) came out with quarterly earnings of $2.53 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $2.32 per share a year ago.
Total revenue from continuing operations increased 9%; constant currency organic revenue grew 8% As reported EPS from continuing operations increased to $1.96; adjusted EPS increased to $2.53 Fiscal 2026 outlook maintained DUBLIN, IRELAND, Feb. 04, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2026 third quarter ended December 31, 2025. Total revenue from continuing operations for the third quarter of fiscal 2026 increased 9% to $1.5 billion compared with $1.4 billion in the third quarter of fiscal 2025.
Peterson Wealth Services lifted its stake in STERIS plc (NYSE: STE) by 191.0% in the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 5,016 shares of the medical equipment provider's stock after buying an additional 3,292 shares during the period. Peterson Wealth
WCM Investment Management LLC lowered its stake in STERIS plc (NYSE: STE) by 44.2% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,171,994 shares of the medical equipment provider's stock after selling 927,121 shares during the quarter. WCM Investment Management
Principal Financial Group Inc. lessened its holdings in STERIS plc (NYSE: STE) by 15.3% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 975,200 shares of the medical equipment provider's stock after selling 176,284 shares during the period. Principal Financial Group Inc. owned 0.99% of
DUBLIN, IRELAND, Jan. 28, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly dividend of $0.63 per share. The dividend is payable on March 19, 2026, to shareholders of record at the close of business on February 17, 2026.
STE enters Q3 earnings with revenues seen up 8% to $1.48B and EPS rising 9.1% to $2.53, supported by strength in Healthcare, AST and Life Sciences.
STERIS plc (NYSE: STE - Get Free Report) has been given a consensus rating of "Moderate Buy" by the nine analysts that are covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month price objective
SG Americas Securities LLC cut its stake in shares of STERIS plc (NYSE: STE) by 88.9% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,481 shares of the medical equipment provider's stock after selling 11,880 shares during the quarter. SG Americas
DUBLIN, IRELAND, Jan. 21, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2026 third quarter results at 9:00 a.m. ET on February 5, 2026. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc.
COLUMBUS, Ohio--(BUSINESS WIRE)--Mettler-Toledo International Inc. (NYSE: MTD) announced today that Michael J. Tokich has been appointed to its Board of Directors, effective February 5, 2026. Mr. Tokich served for over 17 years as Senior Vice President and Chief Financial Officer (“CFO”) at STERIS plc (NYSE: STE), a leading global healthcare and life science provider of products and services, prior to recently transitioning to the role of Senior Financial Advisor at STERIS. Mr. Tokich joined ST.
Fiduciary Family Office LLC cut its stake in shares of STERIS plc (NYSE: STE) by 45.9% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,752 shares of the medical equipment provider's stock after selling 2,333 shares during the